Clonazepam (cas 1622-61-3) for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial

Add time:07/24/2019    Source:sciencedirect.com

BackgroundClonazepam (cas 1622-61-3) is considered to be a first-line treatment for rapid eye movement sleep-related behavior disorder (RBD) in Parkinson's disease (PD). The purpose of this study was to determine the short-term efficacy and safety of clonazepam for the treatment of probable RBD (pRBD) in patients with PD.

We also recommend Trading Suppliers and Manufacturers of Clonazepam (cas 1622-61-3). Pls Click Website Link as below: cas 1622-61-3 suppliers

Prev:Synthesis, characterization and catalytic performances of benzimidazolin-2-iminato actinide (IV) complexes in the Tishchenko reactions for symmetrical and unsymmetrical esters
Next:γ-Rays radiation-induced homopolymerization of trifluorovinyl heptafluoropropyl ether)